Announcements Trials
Browse Landscape

Status

Unknown 2Completed 2Active not recruiting 2

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 98Observational 6Expanded_access 1

Sponsor

Cancer Type

Breast 6Tumor-Agnostic 1Gastrointestinal 1

Conditions

Breast Neoplasms 6Neoplasm, Residual 1Neoplasm Metastasis 1

Interventions

Surveys and Questionnaires 79Blood Specimen Collection 67palbociclib 40Trastuzumab 34Drug Therapy 30Letrozole 29Anastrozole 27Radiotherapy 26Immunohistochemistry 26Mastectomy, Segmental 22Amplified Fragment Length Polymorphism Analysis 22Fulvestrant 21Biopsy 21exemestane 20Tamoxifen 20Interviews as Topic 20Gene Expression Profiling 20Magnetic Resonance Spectroscopy 19ribociclib 18Specimen Handling 18Mastectomy 18Neoadjuvant Therapy 17Paclitaxel 16High-Energy Shock Waves 16Capecitabine 16trastuzumab deruxtecan 15Mammography 15Psychiatric Rehabilitation 14Polymerase Chain Reaction 13Observation 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Observational × Ado-Trastuzumab Emtansine × Breast × Clear all
NCT06663787 2026-05-13

HER2 CR

Nagoya City University

Active not recruiting
50 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT04158258 2026-04-23

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Hoffmann-La Roche

Active not recruiting
2,907 enrolled
Breast

Breast Neoplasms

NCT05945927 2025-10-10

A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

Hoffmann-La Roche

Completed
178 enrolled
Breast

Breast Neoplasms

NCT05754502 2023-03-03

Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Consorzio Oncotech

Unknown
300 enrolled
Breast

Breast Neoplasms

NCT04769050 2022-04-20

Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Fudan University

Unknown
50 enrolled
Breast

Breast Neoplasms

NCT00833963 2019-05-16

MotHER

Genentech, Inc.

Completed
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡